PVRIG2P and cancer: Additionally, increased MAP3K14-AS1 expression was associated with cancer cell resistance to erlotinib, afatinib, neratinib, gefitinib, temsirolimus, dacomitinib, everolimus, lapatinib, and ibrutinib, and increased expression of STAG3L5P-PVRIG2P-PILRB was associated with cancer cell sensitivity to decitabine.